JOHNSON & JOHNSON is 115.7x more valuable than Xenon Pharmaceuticals Inc. by market capitalization ($574.10 B vs $4.96 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | XENE | JNJ |
|---|---|---|
| Market cap | $4.96 B | $574.10 B |
| US-listed rank | #1390 | #20 |
| Revenue (latest FY) | $7.50M | $94.19B |
| Net income (latest FY) | -$345.91M | $26.80B |
| Net margin | -4612.1% | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 763 | 984 |
JOHNSON & JOHNSON is 115.7x more valuable than Xenon Pharmaceuticals Inc. by market capitalization ($574.10 B vs $4.96 B).
In their latest fiscal years, Xenon Pharmaceuticals Inc. reported $7.50M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Xenon Pharmaceuticals Inc. and JOHNSON & JOHNSON, or browse the full rankings.